Related Experiment Video
Updated: Aug 16, 2026

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Published on: June 9, 2017
Binding of madindoline A to the extracellular domain of gp130
Abu Z M Saleh1, Kevin L Greenman, Susan Billings
1Department of Pathology, University of California, Irvine, California 92697, USA.
Abstract:
Elevated levels of IL-6 and IL-11 are associated with multiple myeloma, rheumatoid arthritis, hypercalcemia, cancer cachexia, and Castleman's disease. Madindoline A (MadA), isolated from Streptomyces nitrosporeus K93-0711, specifically inhibits the growth of IL-6- and IL-11-dependent cell lines, most likely by interfering with the homodimerization of gp130. This raises the possibility that MadA can be used as a model compound for the development of novel chemotherapeutic agents. In this report, we demonstrate that the binding of MadA to gp130 is specific and noncovalent, and displays a relatively low affinity. Furthermore, we show that the tricyclic 3a-hydroxytetrahydrofuro[2,3-b]indole (HFI) moiety of MadA alone is not sufficient for binding. Matrix-bound MadA precipitates a protein composed of the extracellular domain of gp130 fused to the Fc region of the immunoglobulin heavy chain. Binding is inhibited in a dose-dependent manner by preincubation with free MadA. The K(D) for binding of MadA to gp130 is 288 microM, as determined by surface plasmon resonance (SPR)-based biosensor analysis. The HFI portion of MadA does not bind to gp130 in either affinity precipitation or SPR analyses. Finally, MadA, but not the HFI portion, inhibits IL-6-dependent Stat3 tyrosine phosphorylation in HepG2 cells.
Insights
Madindoline A (MadA) inhibits interleukin-6 (IL-6) and interleukin-11 (IL-11) signaling by binding to gp130. This compound shows potential as a model for developing new cancer therapies targeting these cytokines.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Elevated levels of IL-6 and IL-11 are linked to various diseases, including multiple myeloma and rheumatoid arthritis.
- These cytokines play crucial roles in cell growth and inflammation.
Purpose of the Study:
- To investigate the mechanism of action of Madindoline A (MadA) in inhibiting IL-6 and IL-11 signaling.
- To determine the binding characteristics of MadA to its target, gp130.
- To assess the therapeutic potential of MadA as a chemotherapeutic agent.
Main Methods:
- Surface plasmon resonance (SPR) was used to analyze the binding kinetics of MadA to gp130.
- Affinity precipitation assays were performed to identify binding interactions.
- Inhibition of Stat3 tyrosine phosphorylation in HepG2 cells was measured to assess functional activity.
Main Results:
- Madindoline A (MadA) specifically binds to gp130 in a noncovalent manner with relatively low affinity (K(D) = 288 microM).
- The 3a-hydroxytetrahydrofuro[2,3-b]indole (HFI) moiety of MadA is not sufficient for binding to gp130.
- MadA, but not the HFI portion, inhibits IL-6-dependent Stat3 tyrosine phosphorylation.
Conclusions:
- Madindoline A (MadA) acts by specifically binding to gp130, interfering with IL-6 and IL-11 signaling pathways.
- MadA's mechanism involves inhibiting Stat3 phosphorylation, suggesting its potential in treating diseases driven by these cytokines.
- MadA serves as a valuable model compound for the development of novel chemotherapeutic agents.
Related Concept Videos
GPCR Desensitization
Activation and Inactivation of G Proteins
IP3/DAG Signaling Pathway
GPCRs Regulate Adenylyl Cylase Activity
Two...
Intracellular Signaling Affects Focal Adhesions
Some...
G-protein Coupled Receptors

